



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## THE PRESENT AND FUTURE

### JACC STATE-OF-THE-ART REVIEW

# Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19



## JACC State-of-the-Art Review

Azita H. Talasaz, PHARM<sup>D</sup>,<sup>a,b,c</sup> Parham Sadeghipour, MD,<sup>d</sup> Maryam Aghakouchakzadeh, PHARM<sup>D</sup>,<sup>a</sup> Isaac Dreyfus, MD,<sup>e</sup> Hessam Kakavand, PHARM<sup>D</sup>,<sup>a</sup> Hamid Ariannejad, MD,<sup>b</sup> Aakriti Gupta, MD, MS,<sup>e,f,g</sup> Mahesh V. Madhavan, MD, MS,<sup>e,f</sup> Benjamin W. Van Tassel, PHARM<sup>D</sup>,<sup>c,h</sup> David Jimenez, MD, PhD,<sup>i</sup> Manuel Monreal, MD, PhD,<sup>j</sup> Muthiah Vaduganathan, MD, MPH,<sup>k</sup> John Fanikos, RPH, MBA,<sup>l</sup> Dave L. Dixon, PHARM<sup>D</sup>,<sup>c,h</sup> Gregory Piazza, MD, MS,<sup>k</sup> Sahil A. Parikh, MD,<sup>e,f</sup> Deepak L. Bhatt, MD, MPH,<sup>k</sup> Gregory Y.H. Lip, MD,<sup>m,n</sup> Gregg W. Stone, MD,<sup>f,o</sup> Harlan M. Krumholz, MD, SM,<sup>g,p,q</sup> Peter Libby, MD,<sup>k</sup> Samuel Z. Goldhaber, MD,<sup>k</sup> Behnood Bikdeli, MD, MS<sup>f,g,k</sup>

### ABSTRACT

Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrates RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management. (J Am Coll Cardiol 2021;78:1635-1654)

© 2021 by the American College of Cardiology Foundation.

From the <sup>a</sup>Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; <sup>b</sup>Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran; <sup>c</sup>Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA; <sup>d</sup>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran; <sup>e</sup>NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York, USA; <sup>f</sup>Clinical Trials Center, Cardiovascular Research Foundation, New York, New York, USA; <sup>g</sup>Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, Connecticut, USA; <sup>h</sup>Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, USA; <sup>i</sup>Respiratory Department, Hospital Ramón y Cajal and Medicine Department, Universidad de Alcalá (Instituto de Ramón y Cajal de Investigación Sanitaria), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Madrid, Spain; <sup>j</sup>Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universidad Católica San Antonio de Murcia, Barcelona, Spain; <sup>k</sup>Division of Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; <sup>l</sup>Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; <sup>m</sup>Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom; <sup>n</sup>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; <sup>o</sup>Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA; <sup>p</sup>Department of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut, USA; and the <sup>q</sup>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Alan Morrison, MD, PhD, served as Guest Associate Editor for this paper. Athena Poppas, MD, FACC, served as Guest Editor-in-Chief for this paper.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Manuscript received May 3, 2021; revised manuscript received August 12, 2021, accepted August 18, 2021.



Listen to this manuscript's audio summary by Editor-in-Chief Dr. Valentin Fuster on JACC.org.

## ABBREVIATIONS AND ACRONYMS

**ACE** = angiotensin-converting enzyme

**ARDS** = acute respiratory distress syndrome

**CETP** = cholesterol ester transfer protein

**COVID-19** = coronavirus disease-2019

**CRP** = C-reactive protein

**DHA** = docosahexaenoic acid

**EPA** = eicosapentaenoic acid

**HDL** = high-density lipoprotein

**ICU** = intensive care unit

**NAD** = nicotinamide adenine dinucleotide

**PCR** = polymerase chain reaction

**RCT** = randomized controlled trial

**SARS-CoV-2** = severe acute respiratory syndrome coronavirus 2

**SOC** = standard of care

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) cellular entry is mediated by attachment to angiotensin-converting enzyme 2 (ACE2). Lipid rafts are plasma membrane microdomains, mainly composed of cholesterol, glycosphingolipids, and phospholipids, capable of changing their composition in response to stimuli that may play a critical role in this process (1). SARS-CoV-2 can trigger an uncontrolled innate inflammatory response (cytokine storm) leading to local and systemic tissue damage commonly seen in advanced coronavirus disease-2019 (COVID-19) (2). Inflammation and resultant endothelial injury might lead to a hypercoagulable state and predispose patients to microthrombosis and macrothrombosis (3,4).

Lipid-modulating agents may limit inflammation and thromboinflammation in COVID-19 by exerting antiviral, anti-inflammatory, immunomodulatory, and antithrombotic effects (5). Moreover, lower high-density lipoprotein (HDL) cholesterol and higher triglyceride levels are associated with worse outcomes in patients with COVID-19 (6). Through lipid raft disruption (7), lipid profile improvement, and other effects, lipid-modulating agents may affect the outcomes of patients with COVID-19. Moreover, as previously seen in other SARS infections, SARS-CoV-2 infection could lead to the *MYD88* gene being highly induced, with resultant activation of the nuclear factor kappa-light-chain-enhancer of the activated B-cell pathway (8,9). Statins have inhibitory effects on this pathway (and a reduction in type 1 interferon) and hyperinflammation (10,11).

The current paper systematically summarizes the randomized controlled trials (RCTs) evaluating lipid-modulating therapies for the prevention or treatment of COVID-19. The presumed mechanisms of action and existing knowledge of RCTs, as well as knowledge gaps that may influence the design of future trials, are highlighted.

## METHODS

**DATA SOURCE AND SEARCH STRATEGY.** ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform were searched to identify RCTs investigating trials of lipid-modulating agents in COVID-19 (date of last search, March 31, 2021). We used key words for COVID-19 or SARS-CoV-2 or coronavirus disease-2019 and statins


## HIGHLIGHTS

- Lipid-modulating agents have pleiotropic effects, including antiviral, immunomodulatory, and antithrombotic properties that might help treat COVID-19.
- Thirty-six randomized controlled trials are evaluating lipid-modulating agents, including statins, omega-3 fatty acids, fibrates, niacin, and cholesteryl ester transfer protein inhibitors, for the treatment of COVID-19.
- Four ongoing randomized controlled trials are investigating omega-3 fatty acid preparations for prevention of COVID-19, and 2 are evaluating niacin in patients beyond the acute phase of illness with COVID-19.

(including atorvastatin, rosuvastatin, simvastatin, fluvastatin, lovastatin, pitavastatin, and pravastatin), fibrates (including fenofibrate, clofibrate, bezafibrate, gemfibrozil, and pemafibrate), ezetimibe, bile acid sequestrants (colesevelam, cholestyramine, and colestipol), proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors (including alirocumab, evolocumab, and inclisiran), omega-3 fatty acids (including icosapent ethyl, eicosapentaenoic acid [EPA], and docosahexaenoic acid [DHA]), niacin, nicotinic acid, nicotinamide, vitamin B<sub>3</sub>, evinacumab, mipomersen, lomitapide, bempedoic acid, and cholesteryl ester transfer protein (CETP) inhibitors (anacetrapib, dalcetrapib, evacetrapib, torcetrapib, and TA-8995).

We separated the RCTs between those with agents used for the treatment of patients with COVID-19 versus those used for preventing the development (or severity) of COVID-19. Study eligibility criteria for inclusion in this review were RCT design with a lipid-modifying agent and description of inclusion and exclusion criteria and the primary outcome at ClinicalTrials.gov or the World Health Organization International Clinical Trials Registry Platform. **Figure 1** describes the search strategy and screening of the studies. For RCTs that met the aforementioned eligibility criteria, we searched MEDLINE with PubMed Interface, Google Scholar, and pre-print servers for published design papers or final result manuscripts.

**SUMMARY OF THE SEARCH RESULTS.** A total of 255 records were screened; 97 required further manual



review. Ultimately, 40 RCTs met the eligibility criteria, of which 36 were related to the management of COVID-19: 17 for statins, 10 for omega-3 fatty acids, 3 for fibrates, 5 for niacin, and 1 for dalcetrapib. In addition, 4 RCTs of omega-3 fatty acids were identified for the prevention of COVID-19. No RCTs were identified for ezetimibe, bile acid sequestrants, proprotein convertase subtilisin/kexin type 9 inhibitors,

evinacumab, mipomersen, lomitapide, bempedoic acid, or CETP inhibitors other than dalcetrapib for the management or prevention of COVID-19.

A summary of the methodological features of the ongoing RCTs categorized according to drug class is provided in [Table 1](#). Factors such as number of enrollees, comparator types, blinding, type of primary outcomes (clinical or surrogate outcomes),

**TABLE 1** Methodological Features of the Ongoing RCTs Categorized According to Drug Class

	Total No. of Patients	Total No. of RCTs	Sample Size		Enrolling Sites		Comparator Types		Blinding			Primary Clinical Outcome	Primary Surrogate Outcome	Blinded Outcome Adjudication	Design Paper Published
			<150 Participants	>150 Participants	Single-Center	Multicenter	Placebo	SOC/No Intervention	Open Label	Single	Double				
Statins	18,215	17	7	10	10	7	5	12	11	1	5	14	3	2	4
Fibrates	1,050	3	1	2	1	2	3	-	-	-	3	3	0	1	-
Niacin	1,200	5	4	1	4	1	5	-	-	-	5	4	1	-	-
Omega-3 fatty acids	21,898	14	8	6	9	5	7	7	2	5	7	8	6	-	3
Dalcetrapib	227	1	-	1	-	1	1	-	-	-	1	1	-	-	-

SOC = standard of care; RCTs = randomized controlled trials.

blinded outcome adjudication, and the existence of published design paper are included. For 7 studies, a design paper or study protocol was available (12-18). Of all RCTs, only 1 has reported the results (at the National Lipid Association Virtual Scientific Sessions) (19).

**POTENTIAL MECHANISMS OF ACTION OF LIPID-MODULATING AGENTS IN PATIENTS WITH COVID-19.** Figure 2 illustrates the potential pathways through which lipid-modulating drugs that have ongoing RCTs may affect outcomes in COVID-19. These agents include statins, omega-3 fatty acids, fibrates, niacin, and dalcetrapib.

Statins inhibit 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (20) and the production of isoprenoid intermediates that are critical for viral entry, immune signaling, and the inflammatory cascade (21). These agents also induce transcription factors such as Krüppel-like factor-2, limiting inflammation and prothrombotic functions of activated endothelial cells (22). Statins exert antioxidant and antiapoptotic effects, potentiate the production of nitric oxide (3,23), and up-regulate transforming growth factor beta receptor III, thereby reducing collagen deposition and pulmonary fibrosis (24).

Data in observational studies, RCTs, and meta-analyses in patients with sepsis are controversial. Two RCTs showed no improvement in acute respiratory distress syndrome (ARDS) versus placebo (25,26). However, some studies suggest a benefit associated with statin use (27). Secondary analysis of the HARP-2 (Hydroxymethylglutaryl-CoA Reductase Inhibition with Simvastatin in Acute Lung Injury to Reduce Pulmonary Dysfunction) trial suggested potential improved survival in patients with a high inflammatory status (28). In a meta-analysis of cohort studies and RCTs of patients with ARDS, statin use was not associated with reduced mortality in patients with acute lung injury but correlated with increased ventilator-free days and reduced Sequential Organ


Failure Assessment scores (29). In COVID-19, a recent single-center retrospective study suggested lower adjusted mortality rates in patients with antecedent statin use compared with nonusers (30).

Omega-3 polyunsaturated fatty acids act as a precursor to lipid mediators that reduce inflammation and may prove beneficial in the COVID-19 inflammatory response (14). Icosapent ethyl, an ethyl ester of EPA, has exhibited anti-inflammatory properties (15). Multiple RCTs have evaluated omega-3 polyunsaturated fatty acids in ARDS. Although individual trial results have been mixed, a meta-analysis found favorable outcomes with regard to ventilator-free days, length of stay in the intensive care unit (ICU), organ failure, and mortality in patients receiving a diet enriched with EPA and gamma-linolenic acid (31,32).

In vitro studies suggest that fenofibrate, a fibric acid derivative, destabilizes the receptor-binding domain of the SARS-CoV-2 spike protein and inhibits the receptor-binding domain that binds to ACE2. This may reduce viral infectivity by up to 70% (33).

Niacin (nicotinic acid, nicotinamide) increases HDL cholesterol levels and may reduce inflammatory mediators. Niacin may also possess antiviral activity through increasing nicotinamide adenine dinucleotide (NAD), as nicotinamide restores poly-adenosine diphosphate-ribose polymerase functions, which inhibit the viral replication and support innate immunity to SARS-CoV-2 (34).

CETP inhibitors (eg, dalcetrapib) raise HDL cholesterol levels, which may have anti-inflammatory properties and inhibit platelet activation (35). However, off-target effects should be considered. In the ILLUMINATE (Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events) trial, torcetrapib (another CETP inhibitor) had favorable effects on lipids but showed an increase in death due to sepsis and increased systolic blood pressure (36).



**SUMMARY OF THE ONGOING RCTs**

A graphical summary of design features of all RCTs for statins, omega-3 fatty acid preparations, fibrates, and niacin for the management of COVID-19 is illustrated in **Figures 3, 4, 5, and 6**, respectively. Also, the section on RCTs for the management of patients with diagnosed COVID-19 begins with statin therapy RCTs, followed by RCTs of omega-3 fatty acid preparations, fibrates, niacin, and dalcetrapib. This sequence does not describe treatment preference. **Figure 7** presents a graphical summary of design features of RCTs for the prevention of COVID-19 (only omega-3 fatty acid had such RCTs). The **Central Illustration** summarizes all ongoing trials per each class of drug. In each section,

discussion of these trials is provided according to the clinical setting.

**RCTs FOR MANAGEMENT OF PATIENTS WITH DIAGNOSED COVID-19. Ongoing RCTs of statin therapy.** Seventeen RCTs of statin therapy have been registered: 16 in the hospitalized setting and 1 in a post-discharge setting. These trials assess either moderate-intensity statin therapy (with simvastatin 40 to 80 mg daily or atorvastatin 20 mg daily or rosuvastatin 5 mg daily) or high-intensity statin therapy (with atorvastatin 40 to 80 mg daily or rosuvastatin 40 mg daily) (37).

**Ongoing RCTs of statin therapy in hospitalized non-ICU patients.** Statins are being evaluated in 14



**FIGURE 3 Ongoing Statin Therapy RCTs in Patients With COVID-19**

Study Name	Inclusion Criteria (Brief <sup>†</sup> )	Exclusion Criteria (Brief <sup>†</sup> )	Sample Size	Study Arms	Duration of Administration	Patient Enrollment Setting <sup>†</sup>	Liver Disease Consideration	DDI Consideration	Primary Outcomes	Primary Outcome Follow-up Duration	Safety Outcomes
<b>INSPIRATION-S</b> NCT04486508	Age 18 years, PCR confirmed COVID-19, estimated survival >24 hours	Pregnancy, antecedent statin use, weight <40 Kg, exclusion from anticoagulation randomization (recent bleed, stroke, trauma, surgery, platelets <50,000/FL), elevated LFTs or liver disease	600	Atorvastatin [20 mg] Placebo	30	Hospitalized	+	-	Composite clinical endpoint	30	LFT rise, Myopathy, Thrombocytopenia, bleeding events
<b>INTENSE-COV</b> NCT04466241	Age 18 years, PCR confirmed COVID-19 with clinical signs of infection within 7 days and treatment naïve.	Pregnancy, lactation, antecedent statin use, severe COVID-19, weight <35kg, GFR<30 mL/min, cirrhosis, elevated LFTs, QTc> 500 ms, HIV	294	Atorvastatin [20 mg] + Lopinavir/ritonavir Lopinavir/ritonavir	10	Hospitalized	+	+	SARS-CoV-2 PCR, CRP	11	Grade 3 or 4
<b>MEDIC-LAUMC</b> NCT04631536	Age 18 years, PCR confirmed COVID-19 admitted for inpatient treatment.	Pregnancy, lactation, antecedent beta-blocker, statin, nicorandil, PDE5 inhibitor or riociguat use, myocarditis, shock, bradycardia (<50 bpm), >1st degree heart block, decompensated heart failure, active liver disease, elevated LFTs	80	Atorvastatin [40 mg] Placebo	14 (or until DC or death)	Hospitalized	+	+	Clinical improvement	30	Any AEs
<b>RESIST</b> CTR1/2020/07/026791	Age 40-75 years, PCR confirmed COVID-19 requiring hospital admission	Pregnancy, lactation, antecedent statin or aspirin use, use of CYP3A4 inhibitors, protease inhibitors, fibrates, niacin, colchicine, critical illness, elevated LFTs, myopathy, recent GI bleeding, coagulopathy, thrombocytopenia	800	Atorvastatin [40 mg] Conventional therapy	10 days or until DC	Hospitalized	+	+	Mortality, Clinical deterioration by WHO scale	10 or until DC	Any AEs, Rhabdomyolysis, bleeding, Rise LFT, Myopathy
<b>STATCO19</b> NCT04380402	Age 18-85 years, suspected COVID-19	Pregnancy, lactation, antecedent statin use, elevated LFTs, CrCL<50 ml/min, treatment with colchicine, CYP3A4 inhibitors, digoxin, fusicidic acid	300	Atorvastatin [40 mg] No Intervention	NP	Hospitalized	+	+	Mortality, Clinical deterioration by WHO scale	30	NP
<b>IRCT</b> 20190727/044343N2	Age 20-50 years, confirmed COVID-19 treated with chloroquine	Antecedent statin use, prior lopinavir/ritonavir use, cardiovascular disease, myositis, or liver damage	100	Atorvastatin [40 mg] SOC	5	Hospitalized	+	+	CRP	5	NP
<b>IRCT</b> 20200408/046990N3	Age 18-65 years, clinical or laboratory diagnosis of mild-moderate COVID-19 admitted to hospital	Pregnancy, lactation, antecedent protease inhibitors, CYP3A4 inhibitors or inducers, colchicine, or fibrates use, active liver disease, elevated LFTs, rhabdomyolysis, GFR<30 ml/min, intubation	40	Atorvastatin [40 mg] Placebo	14	Hospitalized	+	+	Clinical improvement, CRP, radiologic response	14	Any AEs
<b>IRCT</b> 20200906/048638N1	Confirmed COVID-19 by PCR or CT scan	Antecedent statin use, liver failure, non-pulmonary infection	90	Atorvastatin [40 mg] Placebo	7	Hospitalized	+	-	CRP	5	NP
<b>IRCT</b> 20201028/049175N3	Age 18-75 years, PCR confirmed COVID-19	Pregnancy, lactation, antecedent statin use, chronic renal failure, treatment with colchicine, CYP3A4 inhibitors, digoxin, niacin	100	Atorvastatin [40 mg] Placebo	10	Hospitalized	+	-	Mortality, Hospital and ICU length of stay, P/F ratio assessment	Until DC	NP

Statin trials are evaluating patients in different settings. \*See full list of inclusion/exclusion criteria in the original trial records. <sup>†</sup>Enrollment setting includes hospitalized and post-discharge. AEs = adverse events; CK = creatine kinase; CrCl = creatinine clearance; CRP = C-reactive protein; CT = computed tomography; DC = discharge; DDI = drug-drug interaction; FRAIL = Fatigue Resistance, Ambulation, Illnesses, and Loss of weight questionnaire; GFR = glomerular filtration rate; HBV = hepatitis B virus; HCV = hepatitis C virus; LFT = liver function tests; MI = myocardial ischemia; NP = not pointed; P/F ratio = arterial oxygen partial pressure/fractional inspired oxygen; PDE5 = phosphodiesterase type 5; SOC = standard of care; RCTs = randomized controlled trials; C-19-ACS = Preventing cardiac complications of COVID-19 disease with early acute coronary syndrome therapy: a randomized controlled trial; COLSTAT = Colchicine/Statin for the prevention of COVID-19 complications; RESIST = A randomized control trial of statin and aspirin as adjuvant therapy in patients with SARS-CoV-2 infection; STATCO19 = Atorvastatin as adjuvant therapy in COVID-19. All other full study names are provided in the text.

FIGURE 3 Continued

Study Name	Inclusion Criteria (Brief <sup>a</sup> )	Exclusion Criteria (Brief <sup>a</sup> )	Sample Size	Study Arms	Duration of Administration	Patient Enrollment Setting <sup>b</sup>	Liver Disease Consideration	DDI Consideration	Primary Outcomes	Primary Outcome Follow-up Duration	Safety Outcomes
<b>NCT04813471</b>	Age 18-99 years, PCR confirmed COVID-19	Pregnancy, lactation, antecedent statin or nicorandil use, concomitant use of levodopa, PDE-5 inhibitors, riociguat, pulmonary edema, active liver disease, elevated LFTs	70	Atorvastatin [40 mg] SOC	14 days or until DC	ICU	Liver Disease Consideration	DDI Consideration	Clinical Improvement	28	Any AEs
<b>C-19-ACS NCT04333407</b>	Age 40 years or diabetes or known coronary disease or hypertension, PCR confirmed COVID-19	Age <18 years or >85 years, pregnancy, acute coronary syndrome, myocarditis, bleeding diathesis, life expectancy <3 months	3170	Atorvastatin [80 mg] Placebo	28	Floor	Liver Disease Consideration	DDI Consideration	Mortality	30	Any AEs, Bleeding and thrombotic events
<b>HEAL-COVID NCT04801940</b>	Age 18 years, confirmed COVID-19 by laboratory assessment, estimated hospital discharge within 5 days	Pregnancy, lactation, antecedent statin use or complications with statins, use of protease inhibitors or cyclosporine life expectancy < 14 days post-discharge, elevated LFTs, CK> 10 U/LN, Child-Pugh C, or chronic liver disease	2631	Atorvastatin [40 mg] SOC	365	Floor	Liver Disease Consideration	DDI Consideration	Hospital free survival	365	Serious AEs
<b>COLSTAT NCT04472611</b>	Age 18 years, PCR confirmed COVID-19	Pregnancy, lactation, chronic colchicine or corticosteroid use, acute liver disease, GFR < 30mL/min, QTc >500ms, WHO ordinal scale 5-8, rhabdomyolysis, cytopenia	466	Rosuvastatin [40 mg] + Colchicine SOC	During hospitalization	Floor	Liver Disease Consideration	DDI Consideration	COVID 19 Severity by WHO scores	30	NP
<b>NCT04359095</b>	Age 18 years, PCR confirmed COVID-19	Pregnancy, cirrhosis or elevated LFTs, GFR < 30mL/min, advanced or metastatic cancer, FRAIL score of fragility >3	1200	Rosuvastatin [40 mg] + Colchicine Rosuvastatin[40 mg] + Colchicine + Truvada SOC	14 (Truvada for 10 days)	ICU	Liver Disease Consideration	DDI Consideration	Mortality	28	Severe AEs
<b>Ruxo-Sim-20 NCT04348695</b>	Age 18 years, clinical diagnosis of COVID-19 or confirmed PCR or antibodies, grade 3-4 of the WHO 7-point scale of severity, platelets> 50,000/uL, neutrophils> 500/uL	Pregnancy, lactation, impaired gastrointestinal function with impairment of the absorption of simvastatin, concomitant severe bacterial or fungal infection, Co-infection with HIV, HBV, HCV	94	Simvastatin [40 mg] + Ruxolitinib SOC	14	Floor	Liver Disease Consideration	DDI Consideration	COVID 19 Severity by WHO scores	7	Any AEs
<b>REMAP-CAP NCT02735707</b>	Age 18 years, acute illness due to suspected or proven COVID-19	Estimated survival < 24 hours, expected discharge within 48 hours of admission, >14 prior days of inpatient admission	7100	Simvastatin [80 mg] No intervention	28 days or until DC	Floor	Liver Disease Consideration	DDI Consideration	Mortality	90	NP
<b>EPID-COVID-ESTATINAS EUCTR2020-001319-26-ES</b>	Age > 45 years, positive COVID-19 requiring hospital admission and discharged within 3 months	Pregnancy, lactation, antecedent statin use, history of statin intolerance, GFR <30mL / min, prognosis <1-year, liver or heart transplant, myopathy, concomitant cyclosporine use, elevated LFTs	1080	Rosuvastatin [5 mg] No Intervention	NP	Post-Discharge	Liver Disease Consideration	DDI Consideration	Mortality	365	NP

Sample size <100  
 100 ≤ Sample size < 1000  
 1000 ≤ Sample size  
 Intervention arm  
 Comparator arm  
 Statin  
 Duration of Administration  
 Enrollment setting: Floor  
 Enrollment setting: Post-Discharge  
 Enrollment setting: ICU  
 Liver Disease Consideration  
 Drug-Drug Interaction (DDI) consideration  
 Safety outcomes  
 Primary outcome Follow-up Duration



**FIGURE 4 Ongoing RCTs of Omega-3 Fatty Acids in Patients With COVID-19**

Study Name	Inclusion Criteria (Brief <sup>†</sup> )	Exclusion Criteria (Brief <sup>†</sup> )	Sample Size	Study Arms	Duration of Administration	Patient Enrollment Setting <sup>†</sup>	Liver Disease Consideration	DDI Consideration	Primary Outcomes	Primary Outcome Follow-up Duration	Safety Outcomes
<b>KONS-COVID19</b> <b>NCT04357990</b>	Age ≥18 years, confirmed COVID-19, symptoms of upper respiratory infection	Pregnancy, asymptomatic infection, severe pneumonia, antecedent medication by inhalation or naso- and oropharyngeal route, asthma	128	Omega3 Viruxide [Oral and Nasal Spray TDS] Placebo	14	Home	-	-	Time to clinical improvement, hospital admission	28	Any AEs
<b>PREPARE-IT 2</b> <b>NCT04460651</b>	Age ≥40 years, confirmed COVID-19 by RT-PCR with clinical signs of infection within 7 days	Pregnancy or breastfeeding, lack of access to adequate means of communication via the web, contraindication to EPA, anticoagulant use, hemorrhagic diathesis	4000	Icosapent ethyl [4 g BID for 3 days, then 2 g BID for days 4-28] Placebo	28	Home	-	-	Percentage of patients requiring hospitalization	28	Any AEs
<b>VASCE-PA-COVID-19</b> <b>NCT04412018</b>	Age 18-75 years, confirmed COVID-19 within 72 hours with at least one of the following: fever, cough, sore throat, shortness of breath, myalgia	Pregnancy, lactation, life expectancy <3 months, history of MI, stroke, hospitalization for acute lung, liver or kidney disease within last month, active liver disease, acute or chronic pancreatitis	100	Icosapent ethyl [4 g BID for 3 days, then 2 g BID for the subsequent 11 days] Usual care	14	Home	Liver	-	hs-CRP	14	NP
<b>IRCT</b> <b>20200511047399N1</b>	Age ≥18 years, BMI ≥18.5, diabetic patients with confirmed COVID-19	Pregnancy, lactation, Liver, kidney or thyroid abnormalities, pancreatitis, malignancy, menopause, smoking or alcohol use, any abnormality in coagulation study	30	EPA+ DHA [2010 mg] + HCQ HCQ	NP	Home	Liver	-	ESR, CRP	14	LFT rise, fatigue, body pain
<b>NCT04335032</b>	Age ≥18 years, confirmed moderate-severe COVID-19 within 7 days	Pregnancy, lactation, use of immunomodulators, mechanical ventilation, oxygen delivered by high flow nasal cannula, noninvasive positive pressure ventilation, ECMO, multi-organ failure, estimated survival < 48 hours	284	EPA-FFA [1 g BD] Placebo	NP	Home	-	DDI	Mortality, time to treatment failure, P/F ratio assessment	28	Any AEs
<b>NCT04495816</b>	Age ≥18 years, PCR confirmed COVID-19, self-reported new-onset olfactory dysfunction	COVID-19 without self-reported anosmia, severe COVID-19, pre-existing olfactory dysfunction, chronic nasal/sinus infections (rhinosinusitis), endoscopic sinus surgery, nasal steroid spray or irrigation use	126	EPA +DHA [1 g BD] Placebo	42	Home	-	-	Brief Smell Identification Test	42	NP
<b>NCT04507867</b>	Age 30-75, PCR confirmed COVID-19, O <sub>2</sub> sat <90% and respiratory distress, with concomitant diseases such as CVD, diabetes mellitus 2, hypertension, obesity with BMI <35	PO intolerance	240	Concentrated omega 3 fatty acids [10 g BD] SOC	5	Home	-	-	Mortality, hospital stay, qSOFA, ICU admission, LFT, bilirubin, coagulation study, lipid profile, fibrinogen, D-dimer, homocysteine, ferritin, CRP, P/F ratio assessment	21 days or until DC	Any AEs
<b>NCT04553705</b>	Age 25-40 years, suspected COVID-19, CT evidence of viral pneumonia, respiratory rate < 25 /min, O <sub>2</sub> sat>95%	Pregnancy, lactation, Child-Pugh C, estimated survival <24 hours, end-stage lung disease	200	DHA+ EPA [1 g] SOC	30	Home	Liver	-	Clinical improvement, PCR levels, hospital length of stay, lipid profile, CRP, Ferritin, LDH, P/F ratio assessment	30	NP
<b>NCT04647604</b>	Age ≥18 years, suspected or confirmed COVID-19	Pregnancy, lactation, Bleeding diathesis, shock, myocardial infarction, stroke, acute emboli, coma	40	DHA+ EPA [2 mL/kg, IV] Placebo (NaCl)	5	Home	-	-	CRP, lipid profile, inflammatory biomarkers	5	NP
<b>RBR-7Jrxqm</b>	Age 18-65 years, PCR confirmed COVID-19	Pregnancy, artificial nutrition within 15 days, hyperglycemia, hypertriglyceridemia, neutropenia, immunodeficiency/suppression including AIDS, cirrhosis, NYHA class IV heart failure, terminal neurological processes, short life expectancy, shock	50	Fatty acids omega-3 [200 ml] SOC	7	Home	-	-	CRP, TNF-α, IL-6	NP	Any AEs

Sample size <100	Omega3 pearl	Omega-3 Liquid	Duration of Administration	Liver Disease Consideration
100 ≤ Sample size < 1000	Omega3 (Oral/Nasal Spray)	Enrollment setting: Outpatient	Drug-Drug Interction (DDI) consideration	Primary outcome Follow-up Duration
1000 ≤ Sample size	Omega-3 injection	Enrollment setting: Floor	Safety outcomes	
Intervention arm	Omega-3 Sachet			
Comparator arm				

Omega-3 fatty acid preparations are being assessed among non-intensive care unit (ICU) inpatients, and outpatients. \*See full list of inclusion/exclusion criteria in the original trial records. <sup>†</sup>Enrollment setting includes hospitalized non-ICU patients and outpatient settings. BMI = body mass index; CVD = cardiovascular disease; DHA = docosahexaenoic acid; ESR = erythrocyte sedimentation rate; EPA = eicosapentaenoic acid; FFA = free fatty acid; HCQ = hydroxychloroquine; hs-CRP = high-sensitivity C-reactive protein; IL = interleukin; IV = intravenous; LDH = lactate dehydrogenase; NYHA = New York Heart Association; O<sub>2</sub>sat = oxygen saturation; qSOFA = quick Sequential Organ Failure Assessment; TNF = tumor necrosis factor; other abbreviations as in Figure 3. Full study names are provided in the text.

**FIGURE 5** Ongoing RCTs of Fibrates in Patients With COVID-19

Study Name	Inclusion Criteria (Brief <sup>a</sup> )	Exclusion Criteria (Brief <sup>a</sup> )	Sample Size	Study Arms	Duration of Administration	Patient Enrollment Setting <sup>†</sup>	Liver Disease Consideration	DDI Consideration	Primary Outcomes	Primary Outcome Follow-up Duration	Safety Outcomes
<b>FENOC</b> NCT04661930	Age ≥18 years, suspected COVID-19, enrollment within 72 hours of presentation or positive test result	Lactation, fertility treatments, anticoagulant, immunosuppressant, or bile acid sequestrants use, GFR < 30ml/min, acute pre-renal azotemia, MAP<65 mmHg, severe liver disease, gallbladder disease, K>5.0 mEq/L	50	Fenofibrate [145 mg] Placebo	10 days, or until DC	+	+	+	Mortality, D-dimer, CRP, lactate, troponin, ferritin, viral clearance, P/F ratio assessment	14	Any AEs
<b>FERMIN</b> NCT04517396	Age ≥18 years, suspected or confirmed COVID-19, fewer than 14 days since symptom onset	Pregnancy, lactation, treatment with fibrates, warfarin, glimepiride, cyclosporine, tacrolimus, high-dose statin therapy, GFR <30 mL/min, active liver disease, cholelithiasis, uncontrolled hypothyroidism, or rhabdomyolysis	700	Fenofibrate [145 mg] Placebo	10	+	+	+	Composite clinical endpoint	30	Any AEs
<b>PER-099-20</b>	Age ≥18 years, suspected or confirmed COVID-19	Pregnancy, lactation, treatment with fibric acid derivatives, warfarin, glimepiride, cyclosporine, tacrolimus, high-dose statin therapy, GFR < 60 mL/min, active and chronic liver disease, cholelithiasis, hypothyroidism, rhabdomyolysis, acute hepatitis within 12 months, elevated LFTs	300	Fenofibrate [160 mg] Placebo	10	+	+	+	Composite clinical endpoint	30	Any AEs

	Sample size <100		Fibrate		Liver Disease Consideration
	100 ≤ Sample size < 1000		Duration of Administration		Drug-Drug Interaction (DDI) consideration
	1000 ≤ Sample size		Enrollment setting: Floor		Primary outcome Follow-up Duration
	Intervention arm		Enrollment setting: Outpatient		Safety outcomes
	Comparator arm				

Fenofibrate is being evaluated in different settings, including inpatient non-ICU, and outpatient settings. <sup>a</sup>The full list of inclusion and exclusion criteria should be found in the original trial records. <sup>†</sup>Patient enrollment setting includes hospitalized non-ICU patients and outpatient settings. MAP = mean arterial pressure; other abbreviations as in **Figures 3 and 4**. Full study names are provided in the text.

RCTs, with the number of participants ranging from 40 to 7,100 patients in the non-ICU hospital settings. These RCTs include 12 for hospitalized non-ICU patients and 2 that enroll both ICU and non-ICU patients (MEDIC-LAUMC [Managing Endothelial Dysfunction in COVID-19: A Randomized Controlled Trial at LAUMC] and Effectiveness and Safety of Medical

Treatment for SARS-CoV-2 [COVID-19] in Colombia; NCT04359095).

Moderate-intensity statin therapy is being tested in 3 of these 14 RCTs for hospitalized non-ICU patients. The primary outcomes include mortality within 90 days in the REMAP-CAP (Randomized, Embedded, Multifactorial Adaptive Platform Trial for

**FIGURE 6 Ongoing RCTs of Nicotinamide in Patients With COVID-19**

Study Name	Inclusion Criteria (Brief*)	Exclusion Criteria (Brief*)	Sample Size	Study Arms	Duration of Administration	Patient Enrollment Setting*	Liver Disease Consideration	DDI Consideration	Primary Outcomes	Primary Outcome Follow-up Duration	Safety Outcomes
<b>COVID-2</b> NCT04751604	Age ≥ 18 years, confirmed COVID-19 within 7 days	None mentioned	840	Nicotinamide [1 g] Placebo	28	Home	-	-	Frequency of complete symptom resolution	14	NP
<b>Long-COVID</b> NCT04809974	Age 18-65 years, PCR confirmed COVID-19 at least 2 months prior enrollment, SARS-CoV-2 negative PCR at study entry, persistent cognitive difficulties that began around the time of COVID-19, at least two neurological and/or physical symptoms that started at COVID-19 infection	Pregnancy, lactation, any specific CNS disease history, unstable medical condition, history of intubation due to COVID-19, major active or chronic unstable psychiatric illness within the previous year, history of alcohol or other substance abuse	100	Nicotinamide riboside [2 g daily] Placebo	154	Post-Covid-19	-	-	Assessment of cognitive functioning	154	NP
<b>NIRVANA</b> NCT04818216	Age ≥ 18 years, confirmed COVID-19 and evidence of persistent AKI	Pregnancy or lactation, eGFR < 15 mL/min/1.73 m <sup>2</sup> , RRT, cirrhosis or acute liver failure, kidney transplant, blood platelet count < 100,000/microL	100	Nicotinamide riboside [2 cap 250 mg BD] Placebo	10	Home + Hospital	Liver Disease	-	Blood NAD+ level	10	Severe AEs, thrombocytopenia
<b>NR-COVID19</b> NCT04407390	Age ≥ 70 years, confirmed COVID-19, BMI 18-40 kg/m <sup>2</sup> and weight ≥ 40 kg	Need for oxygen therapy, ongoing severe acute respiratory syndrome, cancer diagnosis within last 5 years	100	Nicotinamide riboside [1 g] Placebo	14	Home + Hospital	-	-	Need for oxygen therapy	90	NP
<b>NCT04604704</b>	Age 18- 65 years, PCR confirmed COVID-19, 1-4 months prior enrollment, a fatigue score above 9 in the Chalder Fatigue scale upon enrollment	Pregnancy or lactation, antecedent opioid analgesics use, opioid addiction, opioid dependence or withdrawal syndrome, clinically significant kidney, heart, hepatic impairment, active cancers	60	Nicotinamide [400 mg] + Naltrexone Placebo	84	Post-Covid-19	-	-	Reduction of fatigue in post-COVID-19 syndrome	84	NP

Sample size < 100	Niacin capsule	Enrollment setting: Outpatient	Primary outcome Follow-up Duration
100 ≤ Sample size < 1000	Niacin tablet	Enrollment setting: Floor	Safety outcomes
1000 ≤ Sample size	Niacin solution	Liver Disease Consideration	Post-Covid-19
Intervention arm	Duration of Administration		
Comparator arm			

Niacin is being evaluated in different settings, including inpatient non-ICU, outpatient, and post-acute COVID-19 settings. \*The full list of inclusion and exclusion criteria should be found in the original trial records. †Patient enrollment setting includes hospitalized non-ICU patients, outpatient, and post-acute COVID-19 settings. AKI = acute kidney injury; CNS = central nervous system; eGFR = estimated glomerular filtration rate; NAD = nicotinamide-adenine dinucleotide; RRT = renal replacement therapy; other abbreviations as in Figures 3 and 4. Full study names are provided in the text.

**FIGURE 7** Ongoing RCTs of Omega-3 Fatty Acids for Prevention of COVID-19

Study Name	Inclusion Criteria (Brief*)	Exclusion Criteria (Brief*)	Sample Size	Study Arms	Duration of Administration	Liver Disease Consideration	DDI Consideration	Primary Outcomes	Primary Outcome Follow-up Duration	Safety Outcomes
<b>MITIGATE</b> NCT04505098	Age ≥50 years, no prior history of confirmed COVID-19, established ASCVD	Pregnancy, antecedent IPE or omega-3 fatty acid use, hospitalization for myocardial infarction or PCI within 1 month, triple antithrombotic therapy, stage D heart failure, severe liver disease, GFR<15 mL/min, metastatic cancer, systemic chemotherapy	16500	Icosapent ethyl [2 g BD] Placebo	At least 6 months			Percentage of patients with moderate or severe confirmed viral URIs, worst clinical status due to a confirmed viral URI	365	Any AEs
<b>PREPARE-IT 1</b> NCT04460651	Age ≥18 years, any subject that is circulating and exposed to the public	Previous COVID-19 diagnosis, pregnancy or breastfeeding, receiving one or more doses of any vaccine for SARS-CoV-2 or scheduled to be vaccinated within the next 60 days, contraindication to EPA, anticoagulant use, hemorrhagic diathesis	4000	Icosapent ethyl [4 g BID for 3 days, then 2 g BID for days 4-60] Placebo	60	-	-	Percentage of SARS-CoV-2 positive subjects by RT-PCR or IgG antibodies, severity disease by WHO scale  Highest mean WHO score of COVID-19 in hospitalized patients	60	Any AEs
<b>NCT04483271</b>	Age 30-66 years without confirmed COVID-19	Pregnancy, lactation, hormonal contraceptive use, autoimmune disease, chronic or severe infections	100	Omega3-FA [300 mg] No intervention	60	-	-	IL-1beta, IL-6, TNF-α	60	NP
<b>NCT04658433</b>	Age 35-65 years, without confirmed COVID-19	Pregnancy, lactation, hormonal contraceptives use, CVD, diabetes, autoimmune diseases, chronic or severe infections	100	Omega3-FA [300 mg] No intervention	56	-	-	Serum ACE and ACE2 levels	70	NP

	Sample size <100		Omega3 pearl		Primary outcome Follow-up Duration
	100 ≤ Sample size < 1000		Duration of Administration		Safety outcomes
	1000 ≤ Sample size		Liver Disease Consideration		
	Intervention arm		Drug-Drug Interction (DDI) consideration		
	Comparator arm				

Omega-3 fatty acid preparations are being evaluated in those with moderate to high risk of COVID-19. \*The full list of inclusion and exclusion criteria should be found in the original trial records. AF = atrial fibrillation; ASCVD = atherosclerotic cardiovascular disease; IgG = immunoglobulin G; IL = interleukin; IPE = icosapent ethyl; PCI = percutaneous coronary intervention; RT-PCR = reverse transcription polymerase chain reaction; TNF = tumor necrosis factor; URI = upper respiratory tract infection; other abbreviations as in [Figures 2 to 4](#).

Community-Acquired Pneumonia) study for 7,100 hospitalized non-ICU patients (17) and assessment of COVID-19 severity according to World Health Organization scores within 7 days in the Ruxo-Sim-20 (Study of Ruxolitinib Plus Simvastatin in the

Prevention and Treatment of Respiratory Failure of COVID-19) trial for 94 participants. The comparators of these trials are no intervention and standard of care (SOC), respectively. The third RCT of moderate-intensity statin therapy, INTENSE-COV



**CENTRAL ILLUSTRATION Summary of Ongoing Trials of Lipid-Modulating Agents in Coronavirus Disease-2019**

Lipid-Modulating Agent	Setting in Which the Agent is Being Assessed					Prevention of COVID-19
	Management of COVID-19					
	Outpatient	Floor	ICU	Post-Discharge	Post-Acute COVID-19	
<b>Statins</b>	X	✓ 14 trials	✓ 4 trials	✓ 1 trial	X	X
• Moderate intensity statin • High intensity statin		3 trials 11 trials	1 trial 3 trials	1 trial		
<b>Omega 3-FA Preparations</b>	✓ 4 trials	✓ 6 trials	X	X	X	✓ 4 trials
• Omega 3-FA • IPE	2 trials 2 trials					2 trials 2 trials
<b>Fibrates</b>	✓ 2 trials	✓ 3 trials	X	X	X	X
<b>Niacin</b>	✓ 1 trials	✓ 2 trials	X	X	✓ 2 trials	X
<b>Dalcetrapib</b>	✓ 1 trial	X	X	X	X	X
<b>Other Agents</b>	X	X	X	X	X	X
• Ezetimibe, bile acid sequestrants, PCSK9 inhibitors, bempedoic acid, evinacumab, mipomersen, and lomitapide						

Talasz, A.H. et al. *J Am Coll Cardiol.* 2021;78(16):1635-1654.

Statins are the most frequently studied lipid-modulating agents in randomized controlled trials of patients with coronavirus disease 2019 (COVID-19). Omega-3 fatty acid preparations are the only studied lipid-modulating agents in the prevention of COVID-19. Niacin is the only lipid-modulating agent being studied for post-acute COVID-19. Additional details are provided in [Figures 3, 4, and 5](#).

(Combination therapies to reduce carriage of SARS-Cov-2 and improve outcome of COVID-19 in Ivory Coast: a phase randomized IIB trial), plans to randomize 294 patients to atorvastatin plus lopinavir/ritonavir versus lopinavir/ritonavir for the co-primary outcomes of the proportions of patients with undetectable SARS-CoV-2 polymerase chain reaction (PCR) and C-reactive protein (CRP) <27 mg/L at day 11.

High-intensity statin therapy is being assessed in 11 of 14 ongoing RCTs, with a total of 8,977 hospitalized non-ICU patients with COVID-19. These 11 RCTs are studying high-intensity statin therapy compared with no treatment (2 of 11) or SOC (5 of 11) or placebo (4 of 11). Mortality during hospitalization or within 10 to 30 days is the most common primary outcome in 5 of 11 RCTs with high-intensity statins

for hospitalized non-ICU patients (13,18). The HEAL-COVID (Helping Alleviate the Longer-term Consequences of COVID-19) trial plans to enroll 2,631 participants to explore the effect of high-intensity statin therapy on hospital-free survival within 12 months from enrollment.

Patients with liver disease are excluded in 2 of 3 RCTs with moderate-intensity statins and 8 of 11 trials with high-intensity statins. Considerations of drug-drug interactions at the time of enrollment were evaluated in 1 of 3 RCTs and 8 of 11 RCTs with moderate- and high-intensity statins, respectively.

**Ongoing RCTs of statin therapy in critically ill patients.** Statins are being assessed in 4 RCTs in ICU patients, of which 2 enroll both ICU and non-ICU patients (MEDIC-LAUMC [Managing Endothelial Dysfunction in COVID-19: A Randomized Controlled Trial at LAUMC] and NCT04359095). Two other RCTs include ICU patients only (INSPIRATION-S [The Intermediate versus Standard-dose Prophylactic Anticoagulation and Statin In Critically-ill Patients with COVID-19: An Open Label Randomized Controlled Trial] with 600 participants [12] and Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH [NCT04813471]) with 70 patients with COVID-19.

INSPIRATION-S is the only trial of moderate-intensity statin therapy versus placebo in ICU patients (12). A composite of all-cause mortality, venous or arterial thrombotic events, and treatment with extracorporeal membrane oxygenation within 30 days is the study's primary outcome. The INSPIRATION-S trial completed patient enrollment in April 2021. Thirty-day preliminary results were presented at the 2021 American College of Cardiology Annual Scientific Sessions. Among 587 randomized patients, atorvastatin 20 mg once daily compared with placebo did not result in a significant reduction in the primary composite outcome of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all-cause death with an odds ratio of 0.84 (95% confidence interval [CI]: 0.58-1.21;  $P = 0.35$ ). In the prespecified analysis of patients hospitalized within 7 days of symptom onset, there was a hypothesis-generating reduction in the odds of the primary outcome (odds ratio: 0.60; 95% CI: 0.37-0.99;  $P$  interaction = 0.05) (38).

The remaining RCTs in critically ill patients (3 of 4 trials) are investigating high-intensity statin therapy; 2 of these trials (NCT04813471 and NCT04359095) are studying high-intensity statin therapy compared with SOC. The MEDIC-LAUMC is assessing the effects of high-intensity atorvastatin versus placebo among 80 participants. In addition, 2 of 3 trials of high-intensity

statin therapy (MEDIC-LAUMC and NCT04813471) consider drug-drug interactions before enrollment, and clinical improvement within 1 month is being assessed as the primary outcome in these 2 trials. The other trial, NCT04359095, is assessing the influence of high-intensity statin therapy on mortality within 28 days as the primary outcome among 1,200 ICU or non-ICU patients. Patients with liver disease are excluded in all of the RCTs with moderate- or high-intensity statins for critically ill patients.

**Ongoing RCTs of statin therapy in post-discharge patients.** Rosuvastatin (5 mg daily) is the only statin-based intervention under investigation in the post-discharge setting. The FJD-COVID-ESTATINAS RCT (Multicenter, randomized, controlled, open-label clinical trial to assess the prognostic implications of rosuvastatin treatment in patients discharged after hospitalization for COVID-19) is evaluating rosuvastatin compared with no treatment in 1,080 patients discharged from hospitalization for COVID-19. The primary outcome is a composite of mortality, myocardial infarction, or ischemic stroke within 12 months. Patients with liver disease or concomitant treatment with cyclosporine are excluded. Additional details about ongoing clinical trials of statin therapy are provided in Figure 3.

**Ongoing RCTs of omega-3 fatty acid preparations.** There are 10 ongoing RCTs evaluating the role of omega-3 fatty acid preparations for the management of COVID-19: 6 RCTs in hospitalized non-ICU patients and 4 ongoing RCTs in the outpatient setting.

**Ongoing RCTs of omega-3 fatty acid preparations in hospitalized non-ICU patients.** Omega-3 fatty acids are being evaluated in 6 RCTs, with the number of participants ranging from 30 to 284 patients in the non-ICU hospital settings. Most RCTs (5 of 6) assess the oral use of omega-3 fatty acid preparations compared with SOC (3 of 5) or with placebo (1 of 5). The oral use of omega-3 fatty acid preparations plus hydroxychloroquine compared with hydroxychloroquine alone is assessed in the Comparison of the Effectiveness of Omega-3 and Hydroxychloroquine on Inflammatory Factors, Liver Enzymes, and Clinical symptoms in Diabetic COVID-19 Patients (IRCT20200511047399N1) study. Only one RCT (Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids; NCT04647604) explores intravenous administration of omega-3 fatty acid preparations versus placebo (14). Moreover, 3 of 6 RCTs of hospitalized non-ICU patients have co-primary outcomes, including inflammatory markers and lipid levels. Elevated liver enzymes are being evaluated as the safety outcome only in the



IRCT20200511047399N1 trial. Patients with liver disease are excluded in 2 of the 6 RCTs of omega-3 fatty acid in hospitalized non-ICU patients.

**Ongoing RCTs of omega-3 fatty acid preparations in outpatient setting.** Omega-3 fatty acid preparations are being evaluated in 4 ongoing RCTs for the treatment of COVID-19: KONS-COVID19 (Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19), VASCEPA-COVID-19 (An Investigation on the Effects of Icosapent Ethyl [Vascepa] on Inflammatory Biomarkers in Individuals With COVID-1), PREPARE-IT 2 (Prevention of COVID19 With EPA in Healthcare Providers at Risk-Intervention Trial 2), and the COVID-19 Anosmia Study (NCT04495816) (16).

The KONS-COVID19 trial tests omega-3 inhaled use versus placebo among 128 outpatient participants. The primary outcome is time to clinical improvement within 28 days. The VASCEPA-COVID-19 trial assesses the oral use of icosapent ethyl compared with usual care in a total of 100 outpatient participants. High-sensitivity CRP level is the primary outcome in VASCEPA-COVID-19. Patients with active severe liver disease are excluded in this trial. Initial findings from the VASCEPA-COVID-19 were presented at the National Lipid Association Scientific Sessions (19). The investigators found that the use of icosapent ethyl for 14 days reduced high-sensitivity CRP (3.2 vs 1.6 mg/L;  $P = 0.011$ ) and led to symptom improvement, assessed by using the InFLUenza Patient-Reported Outcome score in outpatients with COVID-19 after 14 days. The PREPARE-IT 2 trial is assessing the effects of icosapent ethyl versus placebo in 2,000 outpatient participants. The impact of oral use of omega-3 fatty acid preparations versus placebo on olfactory performance within 6 weeks among outpatients is under evaluation in the NCT04495816 trial with 126 participants. Additional details about ongoing RCTs of omega-3 fatty acid preparations for treatment of COVID-19 are described in Figure 4.

**Ongoing RCTs of fibrates.** Three RCTs are investigating fibrates in patients with COVID-19. These RCTs are testing fenofibrate versus placebo in hospitalized non-ICU patients: FENOC (Fenofibrate for Patients With COVID-19 Requiring Hospitalization), FERMIN (Fenofibrate as a Metabolic Intervention for COVID-19), and Fenofibrate as a Metabolic Intervention for Coronavirus Disease 2019 [COVID-19]: A Randomized Controlled Trial [PER-099-20]). FERMIN and PER-099-20 also enrolled outpatients. The sample size of these studies ranges from 50 to 700 patients.

The main outcomes in the FENOC study include improvement in laboratory markers, the ratio of arterial oxygen partial pressure to fractional inspired

oxygen, and mortality. The composite endpoint as the primary outcome for the FERMIN and PER-099-20 trials will be a global rank score that grades patients based on survival, need for respiratory/mechanical support, the fraction of inspired oxygen/percent oxygen saturation, the number of days out of the hospital for outpatient participants who are hospitalized after enrollment, and the modified Borg dyspnea scale for the outpatient subset not hospitalized. All these trials consider drug-drug interactions before the enrollment. Patients with active liver disease are excluded in all 3 of these trials. Additional information about these RCTs is summarized in Figure 5.

**Ongoing RCTs of niacin.** Five RCTs of niacin therapy were identified: 2 in hospitalized non-ICU patients, 1 in the outpatient setting, and 2 ongoing RCTs in post-acute COVID-19. All of these trials are studying niacin compared with placebo.

**Ongoing RCTs of niacin in hospitalized non-ICU patients.** Niacin is being assessed in 2 ongoing RCTs for 100 hospitalized non-ICU patients in each trial: NIRVANA (Nicotinamide Riboside in SARS-CoV-2 [COVID-19] Patients for Renal Protection) and NR-COVID19 (Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly). The primary outcomes of these trials are the alteration of blood NAD<sup>+</sup> level within 10 days and the need for oxygen therapy with a follow-up duration of 90 days, respectively. In NIRVANA, thrombocytopenia is being evaluated as the safety outcome, and patients with liver disease are being excluded.

**Ongoing RCTs of niacin in outpatient setting.** The COVit-2 (Improvement of the Nutritional Status Regarding Nicotinamide [Vitamin B3] and the Disease Course of COVID-19) trial is the only study of niacin therapy versus placebo in an outpatient setting; 840 patients plan to be enrolled. The frequency of complete symptom resolution within 2 weeks is the primary outcome.

**Ongoing RCTs of niacin in post-COVID-19 setting.** Niacin is being evaluated in 2 RCTs in the post-COVID-19 setting: Long-COVID (Clinical Trial of Niagen to Examine Recovery in People with Persistent Cognitive and Physical Symptoms After COVID-19 Illness) and Pilot Study Into Low Dose Naltrexone (LDN) and Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>) for Treatment of Patients With Post-COVID-19 Syndrome (NCT04604704). These RCTs assess the oral use of niacin in 100 participants and iontophoresis patches for 60 patients with COVID-19, respectively.

The Long-COVID trial is studying the impact of niacin on the cognitive function of patients with a positive PCR at least 2 months before enrollment. The primary outcome follow-up duration is 22 weeks.

[NCT04604704](#) plans to enroll 60 patients with PCR-confirmed COVID-19 1 to 4 months before enrollment. This trial assesses the reduction in fatigue in post-COVID-19 syndrome within 12 weeks as the primary outcome. Patients with liver disease are excluded in the [NCT04604704](#) trial. Additional details about the RCTs of niacin are illustrated in [Figure 6](#).

**Ongoing RCT of CETP inhibitors.** The dal-COVID (Effect of Dalcetrapib in Patients with Confirmed Mild to Moderate COVID-19) trial is the only study of dalcetrapib (900 mg, 1,800 mg, and 3,600 mg daily) versus placebo and includes 208 outpatients with mild to moderate COVID-19. The primary outcome is time to sustained symptom resolution within 28 days. Patients with liver disease are excluded from the [NCT04676867](#) trial. Drug-drug interactions are being considered before enrollment.

**RCTs FOR PREVENTION OF CONTRACTING COVID-19.** Use of omega-3 fatty acid preparations as a preventive measure against COVID-19 is being investigated in 4 RCTs: MITIGATE (A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults) (15), PREPARE-IT 1 (Prevention of COVID19 With EPA in Healthcare Providers at Risk-Intervention Trial 1), the Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm ([NCT04483271](#)), and the Effect of Omega-3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19 ([NCT04658433](#)).

The MITIGATE and PREPARE-IT 1 trials are studying the effects of icosapent ethyl versus SOC and placebo, respectively. [NCT04483271](#) and [NCT04658433](#) assess omega-3 fatty acid supplements compared with no treatment for 100 patients in each trial. The number of confirmed viral infections and worst clinical status due to a viral upper respiratory infection are the co-primary outcomes for MITIGATE with 16,500 participants. The number of confirmed viral infections is the primary outcome in PREPARE-IT 1 with 2,000 participants. The primary outcomes for the [NCT04483271](#) and [NCT04658433](#) trials are inflammatory markers such as interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and serum ACE and ACE2. Patients with severe liver disease are excluded only in MITIGATE. Additional details about these RCTs are summarized in [Figure 7](#).

## DISCUSSION

The perspective of the COVID-19 disease state has broadened from pneumonia to a systemic multi-organ disease, with systemic inflammation and thrombosis as key features (2,39). The current

review identified 34 RCTs that evaluate the role of lipid-modulating agents in the management of acute COVID-19, 2 RCTs in patients with post-acute COVID-19, and 4 RCTs for prevention of contracting (or severity of) COVID-19. Results from these trials may expand the armamentarium for management of COVID-19. The neutral results of recent RCTs of escalated-dose anticoagulation in critically ill patients with COVID-19 (40,41) may indicate the significance of the maladaptive immune response in severe COVID-19 (42). It is in this context that lipid-modulating agents with pleotropic effects offer possible therapeutic potential (43). The moderate immunomodulating effect of these agents lessens the chance of excessive immunosuppression and superinfection, commonly seen with other anti-inflammatory agents.

Despite such hope, certain methodological limitations of some of the ongoing RCTs deserve attention. These include small sample size, use of primary surrogate outcomes, and lack of blinded outcome adjudication, which hamper the rigor of the trials. More than 1 year into the pandemic, 40 RCTs of lipid-modifying therapies were identified, with only 21 (with total estimated sample size of 7,675) having a double-blind design. The results from only 2 trials have been communicated in preliminary form and none in the peer-reviewed published form. In addition, despite the scientific rationale summarized in this paper, translation to clinical benefit is not assured. Among the immune-modulating therapies, only steroids have shown consistent efficacy in patients with COVID-19 (44-48). The neutral results with ivermectin (49) and hydroxychloroquine (50), and the mixed results with colchicine (51,52) and tocilizumab (53,54), remind us that biological plausibility may not translate into meaningful treatment. Hence, the ongoing lipid-modulating therapy RCTs are of particular interest.

**STATINS AS MULTIPURPOSE DRUGS?** Despite initial concern that statins might increase expression of ACE2 and facilitate SARS-CoV-2 entry with potential deleterious effects, observational studies suggest an association between antecedent statin use and improved survival. In a population-based propensity-matched study of 10,448 patients with COVID-19, Lee et al (55) reported a significant reduction in hazard of death in statin users compared with nonusers (hazard ratio: 0.64; 95% CI: 0.43-0.95;  $P = 0.02$ ). In a retrospective propensity matching analysis of 1,296 patients with COVID-19, Gupta et al (30) reported similar reduction in the odds of death with antecedent statin use (odds ratio: 0.47; 95% CI: 0.36-0.62;  $P < 0.001$ ). Such nonrandomized observational studies are

subject to confounding, including confounding by indication, and require confirmation in ongoing RCTs. There are several limitations to the ongoing statin investigations. Several RCTs do not include thrombotic events among their prespecified outcomes. Quality of life is evaluated in only 3 RCTs. The role of statin therapy in the post-discharge setting for patients with COVID-19 is being studied in only 1 RCT with 1,080 patients but not in the outpatient setting.

**OMEGA-3 POLYUNSATURATED FATTY ACIDS: HOPE OR HYPE?** Anti-inflammatory effects (56) and potential impact on ARDS progression (57) make omega-3 fatty acids worthwhile agents for investigation. Functional limitations and quality of life are evaluated exclusively in outpatient trials, whereas mortality and clinical improvement are evaluated in hospitalized patients. Two trials with considerable sample size evaluate the role of icosapent ethyl in the prevention of contracting COVID-19.

Several limitations apply to the omega-3 fatty acid RCTs. There are relatively few total numbers of patients enrolled in trials of omega-3 fatty acids for the management of COVID-19 (Figure 4). Heterogeneity in use of various formulations (EPA, DHA, or EPA-DHA; ethyl esters vs free fatty acids) and impurities and/or oxidative alterations in unregulated supplement preparations make it more difficult to determine the specific effects of each. Icosapent ethyl will be studied in 2 large outpatient trials (PREPARE-IT 1 and MITIGATE) as a preventive agent but not in the inpatient setting.

**FIBRATES: NEW SPARK FOR A DYING CANDLE?** Despite the declining use for cardiovascular risk reduction (58), fibrates may decrease viral entry and SARS-CoV-2 infectivity by increasing sulfatide levels (59) and inhibiting the receptor-binding domain to ACE2 (33). Strengths of the ongoing fibrate trials include endpoint selection; death, ARDS-related outcomes, inflammatory markers, and invasive mechanical support are the primary outcomes under evaluation. Drug interactions were generally considered with fenofibrate initiation. However, fenofibrate is the only fibrate under investigation in RCTs including patients with COVID-19, and its lack of benefit in cardiovascular disease prevention may raise skepticism regarding its utility in COVID-19.

**NIACIN: TIME FOR A COMEBACK?** Anti-inflammatory effects (34) and potential protection against lung injury (60) have made niacin a target for investigation in COVID-19. Niacin is under evaluation in both acute and post-acute settings. Clinical improvement and symptom resolution are primary outcomes in the

majority of the RCTs. RCTs in the post-COVID-19 setting will evaluate fatigue and cognitive function for 3 to 6 months.

As with fenofibrate, lack of benefit and presence of adverse effects with nicotinic acid seen in prior cardiovascular RCTs (61,62) may dampen enthusiasm for use in COVID-19. The ongoing trials of niacin in COVID-19 are evaluating the role of nicotinamide, another form of niacin that is not typically used as a lipid-modifying agent. Trials in the inpatient and post-acute setting are limited by small sample size, and variability in niacin dosing may lead to heterogeneous results.

**CETP INHIBITORS: ROOM FOR POTENTIAL BENEFIT?** Low HDL levels are associated with increased severity of COVID-19 and correlate with approved biomarkers such as ferritin and D-dimer levels (6). Dalcetrapib will be the first CETP inhibitor to be tested in patients with mild to moderate COVID-19, with time to symptom resolution as the primary outcome. Of note, dalcetrapib did not improve clinical outcomes in those with acute coronary syndromes (63). Among CETP inhibitors, only anacetrapib showed a modest cardiovascular benefit (9% relative risk reduction) (64), whereas torcetrapib (36,65) led to increases in systolic blood pressure and worse cardiovascular outcomes. Findings from dal-COVID will help clarify whether dalcetrapib merits further testing in COVID-19.

**EXPECTING THE UNEXPECTED: POSSIBLE ADVERSE EFFECTS FOR LIPID-MODULATING AGENT TRIALS.** Based on the knowledge from RCTs in cardiovascular diseases, important adverse effects should be monitored when the results of these RCTs accrue. Myopathy is the most common adverse effect of statin use and is managed by conversion to other statin formulations. Severe muscle complications (ie, rhabdomyolysis) are exceedingly rare (66). Rise in liver enzyme levels is another potential but infrequent adverse effect. Fibrates may also increase the risk of myopathy and hepatocyte injury (67). Drug-drug interactions play an important role in this increased risk and are considered in the ongoing COVID-19 RCTs (68). Other risks associated with statin use, including hemorrhagic stroke in those with previous stroke, are not of clinically important magnitude (69-71). New-onset or worsening of atrial fibrillation is a concern with omega-3 fatty acids (72-74), and increased bleeding due to the effects on platelet aggregation should be monitored in the RCT results.

The adverse effects of niacin, specifically nicotinic acid, include flushing, pruritus, gastrointestinal

disorder, thrombocytopenia, hyperuricemia, hyperglycemia, myopathy, and hepatotoxicity (75). However, only nicotinamide is used in COVID-19 studies. The NIRVANA trial assesses thrombocytopenia as a safety outcome and excluded patients with liver disease.

These potential risks are limited by the short duration of treatment in most trials. Of note, the adverse events in massive event-driven cardiovascular trials result from multiple months to years of treatment, whereas the current COVID-19 trials generally have much shorter treatment duration. The possible adverse effects of lipid-modulating agents are illustrated in [Figure 2](#).

## CONCLUSIONS

Lipid-modulating agents may mitigate the multiorgan damage associated with COVID-19 through anti-inflammatory, antiviral, and pleiotropic effects. Findings from ongoing rigorously conducted and adequately powered RCTs can assess the possible efficacy of lipid-modulating agents in the prevention or treatment of various stages of COVID-19 and may open new horizons for research and clinical practice.

**ACKNOWLEDGMENT** The authors express their sincere gratitude to Fatemeh Esmaili, MS, for her kind assistance in the preparation of the figures.

## FUNDING SUPPORT AND AUTHOR DISCLOSURES

Dr Gupta received payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation and from the Ben C. Martin Law Firm for work related to an inferior vena cava filter litigation; received consulting fees from Edward Lifesciences; and holds equity in the health care telecardiology startup Heartbeat Health. Dr Madhavan was supported by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute to Columbia University Irving Medical Center (T32 HL007854). Dr Van Tassel has received research support from Novartis, Swedish Orphan Biovitrum, Olatec Therapeutics, and Serpin Pharma; and is a consultant of R-Pharm and Serpin Pharma. Dr Jimenez has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Leo Pharma, Pfizer, ROVI, and Sanofi; has served as a speaker or a member of a speaker bureau for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Leo Pharma, ROVI, and Sanofi; and has received grants for clinical research from Daiichi-Sankyo, Sanofi, and ROVI. Dr Monreal has served as an advisor or consultant for Sanofi, Leo Pharma, and Daiichi-Sankyo; and has received a nonrestricted educational grant by Sanofi and Bayer to sponsor the Computerized Registry of Patients with Venous Thromboembolism. Dr Vaduganathan has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, and Relypsa; participates in speaker engagements with Novartis and Roche Diagnostics; and participates on clinical endpoint committees for studies sponsored by Galmed, Novartis, and the National Institutes of Health. Dr Fanikos has served as a consultant for Portola, Inc and Pfizer, Inc. Dr Piazza has received research

grant support from BSC, Bayer, Bristol Myers Squibb/Pfizer Alliance, Portola, Amgen, and Janssen; and has received consulting fees from Amgen, Pfizer, and BSC. Dr Parikh has served as a noncompensated advisor to Abbott Vascular, Boston Scientific, Cardiovascular Systems Inc, Cordis, Janssen, Medtronic, and Philips; receives institutional research support from Abbott Vascular, Boston Scientific, SurModics, TriReme, and Veryan Medical; and is a consultant to Abiomed, Inari Medical, Penumbra, and Terumo. Dr Bhatt has served on the advisory board for Cardax, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, Janssen, Level Ex, Medscape Cardiology, MyoKardia, Novo Nordisk, PhaseBio, PLx Pharma, and Regado Biosciences; has served on the Board of Directors for the Boston VA Research Institute, Society of Cardiovascular Patient Care, and ToBeSoft; serves as Chair of the American Heart Association Quality Oversight Committee; has served on the data monitoring committees for Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi-Sankyo), Population Health Research Institute; has received honoraria from the American College of Cardiology (Senior Associate Editor, *Clinical Trials and News*, ACC.org; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, *Harvard Heart Letter*), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), Duke Clinical Research Institute (clinical trial steering committees, including for the PRO-NOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, *Journal of Invasive Cardiology*), *Journal of the American College of Cardiology* (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, *Cardiology Today's Intervention*), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); other, *Clinical Cardiology* (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); has received research funding from Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, and The Medicines Company; has received royalties from Elsevier (Editor, *Cardiovascular Intervention: A Companion to Braunwald's Heart Disease*); has been a site co-investigator, Abbott, Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), and Svelte; has been a trustee for the American College of Cardiology; and has received unfunded research from FlowCo, Merck, and Takeda. Dr Lip is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo (no fees are received personally). Dr Stone has received speaker or other honoraria from Cook, Terumo, and Orchestra Biomed; has been a consultant to Valfix, TherOx, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Miracor, Neovasc, V-Wave, Abiomed, Ancora, MAIA Pharmaceuticals, Vectorious, Reva, Matrizyme, and CardioMech; and has equity/options from Ancora, Cagent, Applied Therapeutics, BioStar family of funds, SpectraWave, Orchestra Biomed, Aria, Cardiac Success, Med Focus family of funds, and Valfix. Dr Krumholz has received personal fees from UnitedHealth, IBM Watson Health, Element Science, Aetna, Facebook, Siegfried & Jensen Law Firm, Arnold & Porter Law Firm, Ben C. Martin Law Firm, and the



National Center for Cardiovascular Diseases (Beijing, China); has ownership in Hugo Health and Refactor Health; has contracts from the U.S. Centers for Medicare & Medicaid Services; and has received grants from Medtronic, the U.S. Food and Drug Administration, Johnson & Johnson, and the Shenzhen Center for Health Information, outside the submitted work. Dr Libby is an unpaid consultant to, or involved in clinical trials for Amgen, AstraZeneca, Beren, Esperion Therapeutics, Ionis Pharmaceuticals, Kowa Pharmaceuticals, Novartis, Pfizer, Sanofi-Regeneron, and XBiotech, Inc; and is a member of the scientific advisory board for Amgen, Corvidia Therapeutics, CSL Behring, DalCor Pharmaceuticals, Genentech, Kowa Pharmaceuticals, Olatec Therapeutics, PlaqueTec, Kancera, Medimmune, Novartis, Novo Nordisk, and XBiotech, Inc. Dr Libby is on the Board of Directors of XBiotech, Inc; and has a financial interest in XBiotech, a company developing therapeutic human antibodies. Dr Libby's interests were reviewed and are managed by Brigham and Women's Hospital and Partners HealthCare in accordance with their conflict of interest policies. Dr Libby's laboratory has received research funding in the

last 2 years from Novartis. Dr Goldhaber has received research support from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Boston Scientific, Daiichi-Sankyo, Janssen, the National Heart, Lung, and Blood Institute, and the Thrombosis Research Institute; and has received consulting fees from Bayer, Agile, Boston Scientific, and Boehringer Ingelheim. Dr Bikdeli is a consulting expert, on behalf of the plaintiff, for litigation related to 2 specific brand models of inferior vena cava filters. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**ADDRESS FOR CORRESPONDENCE:** Dr Behnood Bikdeli, Cardiovascular Medicine Division, Brigham and Women's Hospital, 75 Francis Street, Shapiro 5, Suite 5156, Boston, Massachusetts 02115, USA. E-mail: [bbikdeli@bwh.harvard.edu](mailto:bbikdeli@bwh.harvard.edu) OR [Behnood.bikdeli@yale.edu](mailto:Behnood.bikdeli@yale.edu). Twitter: [@bbikdeli](https://twitter.com/bbikdeli).

## REFERENCES

- Guo H, Huang M, Yuan Q, et al. The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain. *PLoS One*. 2017;12(1):e0170123.
- Cao X. COVID-19: immunopathology and its implications for therapy. *Nat Rev Immunol*. 2020;20(5):269-270.
- Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. *J Am Coll Cardiol*. 2020;75(23):2950-2973.
- Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J*. 2020;41(32):3038-3044.
- Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. *Circ Res*. 2017;120(1):229-243.
- Masana L, Correig E, Ibarretxe D, et al. Low HDL and high triglycerides predict COVID-19 severity. *Sci Rep*. 2021;11(1):1-9.
- Sviridov D, Miller YI, Ballout RA, Remaley AT, Bukrinsky M. Targeting lipid rafts—a potential therapy for COVID-19. *Front Immunol*. 2020:11.
- Sheahan T, Morrison TE, Funkhouser W, et al. MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. *PLoS Pathog*. 2008;4(12):e1000240.
- DeDiego ML, Nieto-Torres JL, Regla-Nava JA, et al. Inhibition of NF- $\kappa$ B-mediated inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. *J Virol*. 2014;88(2):913-924.
- Hilgendorff A, Muth H, Parviz B, et al. Statins differ in their ability to block NF- $\kappa$ B activation in human blood monocytes. *Int J Clin Pharmacol Ther*. 2003;41(9):397-401.
- Yuan S. Statins may decrease the fatality rate of Middle East respiratory syndrome infection. *MBio*. 2015;6(4).
- Bikdeli B, Talasaz AH, Rashidi F, et al. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: rationale and design of the INSPIRATION/INSPIRATION-S studies. *Thromb Res*. 2020;196:382-394.
- Ghati N, Roy A, Bhatnagar S, et al. Atorvastatin and aspirin as adjuvant therapy in patients with SARS-CoV-2 infection: a structured summary of a study protocol for a randomised controlled trial. *Trials*. 2020;21(1):1-3.
- Arnardottir H, Pawelzik S-C, Öhlund Wistbacka U, et al. Stimulating the resolution of inflammation through omega-3 polyunsaturated fatty acids in COVID-19: rationale for the COVID-Omega-F trial. *Front Physiol*. 2021;11:1748.
- Ambrosy AP, Malik UI, Thomas RC, et al. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). *Am Heart J*. 2021;235:54-64.
- Lerner D, Garvey K, Arrighi-Allison A, et al. Letter to the editor: study summary—randomized control trial of omega-3 fatty acid supplementation for the treatment of COVID-19 related olfactory dysfunction. *Trials*. 2020;21(1):942.
- REMAP-CAP. Randomized, Embedded, Multi-factorial Adaptive Platform trial for Community-Acquired Pneumonia, Domain-Specific Appendix: Statin Therapy REMAP-CAP: REMAP-CAP; July 2020. [https://static1.squarespace.com/static/5cde3c7d9a69340001d79ffe/t/5f1bbb351849fd6f694bb8b5/1595652928010/REMAP-CAP+Domain-Specific+Appendix+--+Simvastatin+Domain+V1.1+--+23+July+2020\\_WM.pdf](https://static1.squarespace.com/static/5cde3c7d9a69340001d79ffe/t/5f1bbb351849fd6f694bb8b5/1595652928010/REMAP-CAP+Domain-Specific+Appendix+--+Simvastatin+Domain+V1.1+--+23+July+2020_WM.pdf)
- Kanagarantam P, Francis DP, Cole G, et al. Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomised controlled trial. Joint Research Compliance Office: Joint Research Compliance Office; 2020. <https://storage.googleapis.com/found-by-me/documents/trials/c-19-acs/Protocol%20C-19-ACS.pdf>
- Bhatt DL, Kumbhani DJ, Eagle KA. Effects of icosapent ethyl on inflammatory biomarkers in individuals with COVID-19—VASCEPA COVID-19 CardioLink-9. Paper presented at: National Lipid Association Virtual Scientific Sessions. December 12, 2020.
- Krisko TI, Armstrong EJ, Cohen DE. Pharmacology of cholesterol and lipoprotein metabolism. In: Principles of Pharmacology: The Pathophysiological Basics of Drug Therapy: Fourth Edition. Wolters Kluwer Health. 2016.
- Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against influenza. *BioMed Res Int*. 2014;2014.
- SenBanerjee S, Lin Z, Atkins GB, et al. KLF2 Is a novel transcriptional regulator of endothelial proinflammatory activation. *J Experiment Med*. 2004;199(10):1305-1315.
- Merx MW, Weber C. Statins in the intensive care unit. *Curr Opin Crit Care*. 2006;12(4):309-314.
- Sun F, Duan W, Zhang Y, et al. Simvastatin alleviates cardiac fibrosis induced by infarction via up-regulation of TGF- $\beta$  receptor III expression. *Br J Pharmacol*. 2015;172(15):3779-3792.
- McAuley DF, Laffey JG, O'Kane CM, et al. Simvastatin in the acute respiratory distress syndrome. *N Engl J Med*. 2014;371:1695-1703.
- Truwit JD, Bernard GR, Matthay MA, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. *N Engl J Med*. 2014;370(23):2191-2200.
- Parihar SP, Guler R, Brombacher F. Statins: a viable candidate for host-directed therapy against infectious diseases. *Nat Rev Immunol*. 2019;19(2):104-117.
- Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. *Lancet Respir Med*. 2018;6(9):691-698.
- Feng Y. Efficacy of statin therapy in patients with acute respiratory distress syndrome/acute lung injury: a systematic review and meta-analysis. *Eur Rev Med Pharmacol Sci*. 2018;22(10):3190-3198.

30. Gupta A, Madhavan MV, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. *Nat Commun*. 2021;12(1):1-9.
31. Pontes-Arruda A, DeMichele S, Seth A, Singer P. The use of an inflammation-modulating diet in patients with acute lung injury or acute respiratory distress syndrome: a meta-analysis of outcome data. *J Parenter Enter Nutr*. 2008;32(6):596-605.
32. Rogero MM, de C Leão M, Santana TM, et al. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. *Free Radic Biol Med*. 2020;156:190-199.
33. Davies SP, Mycroft-West CJ, Pagani I, et al. The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models. *bioRxiv*. January 11, 2021. <http://doi.org/10.1101/2021.01.10.426114>
34. Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside—the current state of research and therapeutic uses. *Nutrients*. 2020;12(6):1616.
35. Sorokin AV, Karathanasis SK, Yang ZH, Freeman L, Kotani K, Remaley AT. COVID-19—associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches. *FASEB J*. 2020;34(8):9843-9853.
36. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*. 2007;357(21):2109-2122.
37. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019;73(24):e285-e350.
38. Bikkeli B, Talasz AH, Sharif-Kashani B, et al. *INSPIRATION-S Investigators. Atorvastatin vs placebo in patients with COVID-19 admitted to the ICU: the INSPIRATION-S Trial*. American College of Cardiology Scientific Sessions; May 2021. Slides available at: <https://www.acc.org/education-and-meetings/image-and-slide-gallery/media-detail?id=9DF17809F35C4CA6B149C64C9D700AC6>
39. Mechanick JI, Rosenson RS, Pinney SP, Mancini DM, Narula J, Fuster V. Coronavirus and cardiometabolic syndrome: JACC Focus Seminar. *J Am Coll Cardiol*. 2020;76(17):2024-2035.
40. Sadeghipour P, Talasz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. *JAMA*. 2021;325(16):1620-1630.
41. Goligher EC, Bradbury CA, McVerry BJ, et al. Therapeutic anticoagulation in critically ill patients with Covid-19—preliminary report. *medRxiv*. 2021.
42. Talasz AH, Sadeghipour P, Kakavand H, et al. Recent randomized trials of antithrombotic therapy for patients with COVID-19: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021;77(15):1903-1921.
43. Lee C, Choi WJ. Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective. *Arch Pharm Res*. 2021:1-18.
44. Wootton D. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. 2021;384(8):693-704.
45. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. *JAMA*. 2020;324(13):1307-1316.
46. Dequin P-F, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. *JAMA*. 2020;324(13):1298-1306.
47. Sterne JA, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *JAMA*. 2020;324(13):1330-1341.
48. Ramakrishnan S, Nicolau DV Jr, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. *Lancet Respir Med*. 2021;9(7):763-772.
49. López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial. *JAMA*. 2021;325(14):1426-1435.
50. Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. *JAMA*. 2020;324(21):2165-2176.
51. Devereux SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. *JAMA Network Open*. 2020;3(6):e2013136-e.
52. Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blind, placebo-controlled clinical trial. *RMD Open*. 2021;7(1):e001455.
53. Lan S-H, Lai C-C, Huang H-T, Chang S-P, Lu L-C, Hsueh P-R. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. *Int J Antimicrob Agents*. 2020;56(3):106103.
54. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med*. 2020;383(24):2333-2344.
55. Lee H-Y, Ahn J, Park J, et al. Beneficial effect of statins in COVID-19-related outcomes—brief report: a national population-based cohort study. *Arterioscler Thromb Vasc Biol*. 2021;41(3):e175-e182.
56. Duvall MG, Levy BD. DHA-and EPA-derived resolvins, protectins, and maresins in airway inflammation. *Eur J Pharmacol*. 2016;785:144-155.
57. Darwesh AM, Bassiouni W, Sosnowski DK, Seubert JM. Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications? *Pharmacol Ther*. 2020:107703.
58. Everhart A, Desai NR, Dowd B, et al. Physician variation in the de-adoption of ineffective statin and fibrate therapy. *Health Serv Res*. Published online February 10, 2021. <https://doi.org/10.1111/1475-6773.13630>
59. Buschard K. Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. *Med Hypotheses*. 2020;143:110127.
60. Nagai A, Matsumiya H, Hayashi M, Yasui S, Okamoto H, Konno K. Effects of nicotinamide and niacin on bleomycin-induced acute injury and subsequent fibrosis in hamster lungs. *Experiment Lung Res*. 1994;20(4):263-281.
61. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med*. 2011;365(24):2255-2267.
62. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med*. 2014;371(3):203-212.
63. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med*. 2012;367(22):2089-2099.
64. HPS3/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, et al. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med*. 2017;377(13):1217-1227.
65. Bikkeli B, Barreto-Filho JA. Reducing the cardiovascular disease burden: justified means for getting to the end. *Circ Cardiovasc Qual Outcomes*. 2012;5(4):580-586.
66. Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. *N Engl J Med*. 2020;383(22):2182-2184.
67. Chen Y-Q, Zhao S-p, Ye H-J. Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial. *Curr Med Res Opin*. 2020;36(6):941-945.
68. Talasz AH, Kakavand H, Van Tassel B, et al. Cardiovascular complications of COVID-19: pharmacotherapy perspective. *Cardiovasc Drugs Ther*. 2020:1-11.
69. Adhyaru BB, Jacobson TA. Safety and efficacy of statin therapy. *Nat Rev Cardiol*. 2018;15(12):757-769.
70. Pandit A, Kumar P, Kumar A, Chakravarty K, Misra S, Prasad K. High-dose statin therapy and



risk of intracerebral hemorrhage: a meta-analysis. *Acta Neurol Scand*. 2016;134(1):22–28.

**71.** Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence—focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *Eur Heart J*. 2018;39(27):2526–2539.

**72.** Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for

hypertriglyceridemia. *N Engl J Med*. 2019;380(1):11–22.

**73.** Kalstad AA, Myhre PL, Laake K, et al. Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction: a randomized controlled trial. *Circulation*. 2021;143(6):528–539.

**74.** Lombardi M, Carbone S, Del Buono MG, et al. Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-

analysis of randomized controlled trials. *Eur Heart J Cardiovasc Pharmacother*. 2021;7(4):e69–e70.

**75.** Huber R, Wong A. Nicotinamide: an update and review of safety & differences from niacin. *Skin Therapy Lett*. 2020;25(5):7–11.

---

**KEY WORDS** COVID-19, fibrate, lipid-modulating agent, niacin, omega-3, statin